Queens Man Sentenced to More Than Years for Sexually Abusing Three Minor Girls at Fort Hamilton Army Base
NEW YORK - November 02, 2015 - Earlier today, in federal court in Brooklyn, Fausto Bonifaz was sentenced to 151 months’ imprisonment, to be followed by 20 years of supervised release, for coercing and enticing three minors, ages 12 and 13, to engage in sexual activity. As part of the sentence, the defendant will be required to register as a sex offender. Bonifaz pled guilty in March 2015.
The sentence was announced by Robert L. Capers, United States Attorney for the Eastern District of New York.
Bonifaz began to sexually abuse the victims in 2009, when they were 12 and 13 years old. Over the course of the next year, he sexually assaulted one of the victims on a weekly basis at her home at the Fort Hamilton Army base, which he admitted at the time of his guilty plea and at sentencing. At sentencing, the government presented evidence that Bonifaz also abused two other minor victims, again at the Fort Hamilton Army base.
In announcing the sentence, Mr. Capers expressed his grateful appreciation to the Federal Bureau of Investigation, the agency responsible for leading the government’s investigation.
The sentencing proceeding took place before Sr. United States District Judge Raymond J. Dearie.
The government’s case is being prosecuted by Assistant United States Attorney Tiana Demas.
This case was brought as part of Project Safe Childhood, a nationwide initiative to protect children by combatting the sexual exploitation and abuse of minors. Led by United States Attorneys’ Offices around the country, Project Safe Childhood marshals federal, state, and local resources to apprehend and prosecute individuals who exploit children and to identify and rescue victims. For more information about Project Safe Childhood, please visit www.usdoj.gov/psc.
The Defendant:
Name: FAUSTO BONIFAZ
Age: 40
Queens, New York
U.S. Attorney’s Office
Eastern District of New York
This content has been reproduced from its original source.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
